Accelerated Integrated Drug Discovery Services
From Hypothesis to Lead in Record Time, A Unified, AI-Empowered Discovery Engine
We fuse biology, chemistry, informatics, and AI under one roof to deliver optimized leads, faster. As part of PI Health Sciences’ commitment to integrated innovation, our platform unites scientific depth with digital precision, transforming fragmented discovery into a continuous, intelligent feedback process.
Traditional drug discovery is fragmented: biology teams, chemistry teams, and in silico teams often operate in silos, creating delays, miscommunication, and lost insight. Our integrated, AI-driven discovery ecosystem embeds cross-disciplinary teams in a single, connected workflow, bringing together biology, medicinal chemistry, structural biology, DMPK modeling, and AI/ML pipelines that communicate seamlessly.
By integrating tools like Cresset Torx®, Agentic AI, SciFinder®, Reaxys®, and Synthia®, our teams design, predict, and prioritize better molecules faster through iterative feedback loops, real-time data sharing, and dynamic decision-gating, dramatically reducing cycle times and attrition.
Capabilities
Integrated DrugDiscovery
Why Partner With Us?
Proven Track Record
Delivered a kinase lead in 6 months via AI-chemistry loop.
Lower Risk
Early detection of liabilities via predictive models.
Speed & Efficiency
Compressed timelines via parallelization.
Transparency
Shared dashboards, audit trails, and decision rationales.
Flexible Engagement Models
Full program execution, modular support, or co-development partnerships.
Frequently asked questions
Why partner with PI Health Sciences for Integrated Drug Discovery instead of a fragmented CRO model?
PI Health Sciences delivers an integrated, chemistry-led IDD framework where target readiness, hit identification, hit-to-lead, and early lead optimization are executed under unified scientific oversight. This structure preserves decision logic, reduces iterative rework across stages, and enables development-informed optimization from the outset.
How are target identification and hit identification handled in the IDD workflow?
Target and hit identification are executed through tightly integrated biology and chemistry teams supported by computational and AI tools. Biological insights, structural data, and in-silico prioritization are aligned early to ensure only tractable, developable targets and high-confidence hits advance into hit-to-lead programs.
How does PI Health Sciences ensure transparency and data integrity?
All discovery programs are supported by shared dashboards, structured data capture, audit trails, and clearly documented decision rationales. This transparency enables sponsors to track progress, understand scientific decisions, and maintain regulatory-ready documentation.
How is hit-to-lead and lead optimization executed within the PI Health Sciences IDD model?
Hit-to-lead and lead optimization are driven by iterative medicinal chemistry using multi-parameter optimization to balance SAR, physicochemical properties, and early developability indicators. Design decisions incorporate synthetic feasibility, impurity risk, and preliminary scalability considerations to support efficient progression into development.
How does an AI-empowered discovery engine accelerate lead identification?
Our AI-empowered discovery platform combines in-silico modeling, predictive analytics, and real-time experimental feedback to prioritize compounds based on relative performance rather than isolated predictions. Continuous AI-chemistry-biology feedback loops reduce design–make–test–analyze (DMTA) cycle times and improve lead quality early in discovery.
Insights & Resources
Experience case studies from around the services
Contact Us
Connect with PI Health Sciences to explore how our customized pharmaceutical development services can streamline your molecule’s journey from concept to market with precision and confidence.